ROIV
Roivant Sciences Ltd.
Biotechnology
Market Cap$20.91B
5Y Perf.+183.4%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
ROIV vs IMVT
Revenue, margins, valuation, and 5-year total return — side by side.
IMVT
Immunovant, Inc.
Biotechnology
Market Cap$5.83B
5Y Perf.-37.9%
ROIV vs IMVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ROIV | IMVT |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $20.91B | $5.83B |
| Revenue (TTM) | $13M | $0.00 |
| Net Income (TTM) | $-809M | $-464M |
| Gross Margin | 91.2% | — |
| Operating Margin | -91.3% | — |
| Total Debt | $100M | $98K |
| Cash & Equiv. | $2.72B | $714M |
ROIV vs IMVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ROIV
IMVT
| Stock | Dec 20 | May 26 | Return |
|---|---|---|---|
| Roivant Sciences Lt… (ROIV) | 100 | 283.4 | +183.4% |
| Immunovant, Inc. (IMVT) | 100 | 62.1 | -37.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ROIV vs IMVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ROIV leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. Immunovant, Inc. is the stronger pick specifically for profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
ROIV
Roivant Sciences Ltd.
The Income Pick
ROIV carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- Dividend streak 1 yrs, beta 0.95
- Lower volatility, beta 0.95, Low D/E 1.9%, current ratio 33.47x
- Beta 0.95, current ratio 33.47x
Best for: income & stability and sleep-well-at-night
IMVT
Immunovant, Inc.
The Growth Play
IMVT is the clearest fit if your priority is growth exposure and long-term compounding.
- EPS growth -45.2%
- 188.1% 10Y total return vs ROIV's 177.1%
- 3.2% margin vs ROIV's -60.8%
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ROIV | -11.2% revenue growth vs IMVT's -21.3% |
| Quality / Margins | IMVT | 3.2% margin vs ROIV's -60.8% |
| Stability / Safety | ROIV | Beta 0.95 vs IMVT's 1.37 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | ROIV | +160.6% vs IMVT's +107.2% |
| Efficiency (ROA) | ROIV | -15.5% ROA vs IMVT's -44.1% |
ROIV vs IMVT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2024
Segment breakdown not available.
ROIV vs IMVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLROIVLAGGINGIMVT
IMVTImmunovant, Inc.
1leads
ROIVRoivant Sciences Ltd.
3leads
6 Total Categories
CATEGORYLEADERvs IMVTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
IMVT1/1
Valuation MetricsMultiples, price ratios, and targets
ROIV2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ROIV5/7
Total Returns1Y, 3Y, 5Y total returns with dividends
ROIV5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
IMVT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
ROIV and IMVT operate at a comparable scale, with $13M and $0 in trailing revenue.
| Metric | ROIVRoivant Sciences … | IMVTImmunovant, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $13M | $0 |
| EBITDAEarnings before interest/tax | -$1.2B | -$487M |
| Net IncomeAfter-tax profit | -$809M | -$464M |
| Free Cash FlowCash after capex | -$767M | -$423M |
| Gross MarginGross profit ÷ Revenue | +91.2% | — |
| Operating MarginEBIT ÷ Revenue | -91.3% | — |
| Net MarginNet income ÷ Revenue | -60.8% | — |
| FCF MarginFCF ÷ Revenue | -57.6% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | -77.8% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -2.7% | +19.7% |
IMVT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
ROIV leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | ROIVRoivant Sciences … | IMVTImmunovant, Inc. |
|---|---|---|
| Market CapShares × price | $20.9B | $5.8B |
| Enterprise ValueMkt cap + debt − cash | $18.3B | $5.1B |
| Trailing P/EPrice ÷ TTM EPS | -120.08x | -10.50x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 719.58x | — |
| Price / BookPrice ÷ Book value/share | 4.03x | 6.14x |
| Price / FCFMarket cap ÷ FCF | — | — |
ROIV leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
ROIV leads this category, winning 5 of 7 comparable metrics.
Profitability & Efficiency
ROIV delivers a -16.3% return on equity — every $100 of shareholder capital generates $-16 in annual profit, vs $-47 for IMVT. IMVT carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to ROIV's 0.02x. On the Piotroski fundamental quality scale (0–9), ROIV scores 5/9 vs IMVT's 2/9, reflecting solid financial health.
| Metric | ROIVRoivant Sciences … | IMVTImmunovant, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -16.3% | -47.1% |
| ROA (TTM)Return on assets | -15.5% | -44.1% |
| ROICReturn on invested capital | -50.4% | — |
| ROCEReturn on capital employed | -16.4% | -66.1% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 2 |
| Debt / EquityFinancial leverage | 0.02x | 0.00x |
| Net DebtTotal debt minus cash | -$2.6B | -$714M |
| Cash & Equiv.Liquid assets | $2.7B | $714M |
| Total DebtShort + long-term debt | $100M | $98,000 |
| Interest CoverageEBIT ÷ Interest expense | — | — |
ROIV leads this category, winning 5 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
ROIV leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ROIV five years ago would be worth $29,082 today (with dividends reinvested), compared to $17,386 for IMVT. Over the past 12 months, ROIV leads with a +160.6% total return vs IMVT's +107.2%. The 3-year compound annual growth rate (CAGR) favors ROIV at 47.6% vs IMVT's 14.1% — a key indicator of consistent wealth creation.
| Metric | ROIVRoivant Sciences … | IMVTImmunovant, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | +31.4% | +10.7% |
| 1-Year ReturnPast 12 months | +160.6% | +107.2% |
| 3-Year ReturnCumulative with dividends | +221.7% | +48.4% |
| 5-Year ReturnCumulative with dividends | +190.8% | +73.9% |
| 10-Year ReturnCumulative with dividends | +177.1% | +188.1% |
| CAGR (3Y)Annualised 3-year return | +47.6% | +14.1% |
ROIV leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — ROIV and IMVT each lead in 1 of 2 comparable metrics.
Risk & Volatility
ROIV is the less volatile stock with a 0.95 beta — it tends to amplify market swings less than IMVT's 1.37 beta. A beta below 1.0 means the stock typically moves less than the S&P 500.
| Metric | ROIVRoivant Sciences … | IMVTImmunovant, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.95x | 1.37x |
| 52-Week HighHighest price in past year | $30.33 | $30.09 |
| 52-Week LowLowest price in past year | $10.58 | $13.36 |
| % of 52W HighCurrent price vs 52-week peak | +95.0% | +95.3% |
| RSI (14)Momentum oscillator 0–100 | 50.9 | 55.7 |
| Avg Volume (50D)Average daily shares traded | 4.9M | 1.4M |
Evenly matched — ROIV and IMVT each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates ROIV as "Buy" and IMVT as "Buy". Consensus price targets imply 58.7% upside for IMVT (target: $46) vs 15.2% for ROIV (target: $33).
| Metric | ROIVRoivant Sciences … | IMVTImmunovant, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $33.20 | $45.50 |
| # AnalystsCovering analysts | 14 | 23 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 1 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +6.2% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ROIV leads in 3 of 6 categories (Valuation Metrics, Profitability & Efficiency). IMVT leads in 1 (Income & Cash Flow). 1 tied.
Best OverallRoivant Sciences Ltd. (ROIV)Leads 3 of 6 categories
Loading custom metrics...
ROIV vs IMVT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is ROIV or IMVT a better buy right now?
Analysts rate Roivant Sciences Ltd.
(ROIV) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ROIV or IMVT?
Over the past 5 years, Roivant Sciences Ltd.
(ROIV) delivered a total return of +190. 8%, compared to +73. 9% for Immunovant, Inc. (IMVT). Over 10 years, the gap is even starker: IMVT returned +188. 1% versus ROIV's +177. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ROIV or IMVT?
By beta (market sensitivity over 5 years), Roivant Sciences Ltd.
(ROIV) is the lower-risk stock at 0. 95β versus Immunovant, Inc. 's 1. 37β — meaning IMVT is approximately 44% more volatile than ROIV relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 2% for Roivant Sciences Ltd. — giving it more financial flexibility in a downturn.
04Which is growing faster — ROIV or IMVT?
On earnings-per-share growth, the picture is similar: Immunovant, Inc.
grew EPS -45. 2% year-over-year, compared to -104. 6% for Roivant Sciences Ltd.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ROIV or IMVT?
Immunovant, Inc.
(IMVT) is the more profitable company, earning 0. 0% net margin versus -592. 0% for Roivant Sciences Ltd. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IMVT leads at 0. 0% versus -34. 5% for ROIV. At the gross margin level — before operating expenses — ROIV leads at 96. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — ROIV or IMVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is ROIV or IMVT better for a retirement portfolio?
For long-horizon retirement investors, Roivant Sciences Ltd.
(ROIV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 95), +177. 1% 10Y return). Both have compounded well over 10 years (ROIV: +177. 1%, IMVT: +188. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between ROIV and IMVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.